Chondroblastoma is a rare and benign bone tumor that primarily affects the epiphyses (ends) of long bones, most commonly in the knee or proximal humerus. It predominantly occurs in individuals between the ages of 10 and 25. Chondroblastoma is characterized by the presence of chondroblasts, which are immature cartilage-forming cells. Symptoms may include localized pain, swelling, and reduced joint mobility. Radiographically, chondroblastoma typically appear as well-defined lesions with a characteristic soap-bubble or eccentric appearance on X-rays. Diagnosis is confirmed through imaging studies and often requires a biopsy for histological examination. Treatment options for chondroblastomas include curettage (surgical removal of the tumor) with or without bone grafting. While chondroblastomas are generally considered benign, they can be locally aggressive, and recurrence is possible. Regular follow-up and monitoring are crucial to detect any recurrence or complications. Comprehensive understanding of chondroblastomas is essential in orthopaedics, guiding appropriate diagnostic and therapeutic interventions for individuals affected by this relatively rare bone tumor.
Title : The UK profemur recall and implant cobaltism
Stephen S Tower, University of Alaska Anchorage, United States
Title : The tomographic phenotype and the genotype of wormain bones
Ali Al Kaissi, National Ilizarov Medical Research Center for Traumatology and Orthopaedics, Russian Federation
Title : New treatment of muscle contracture and joint contracture through muscle regeneration with mitochondrial dynamics
Ki Ji Lee, Busan Medical University, Korea, Republic of
Title : New treatment of sarcopenia through muscle regeneration with mitochondrial dynamics
Ki Ji Lee, Busan Medical University, Korea, Republic of
Title : The prevalence and association of self-reported depression symptoms with musculoskeletal pain and quality of life among pregnant women
Youssef Masharawi, Tel Aviv University, Israel
Title : Bipolar hemiarthroplasty under local anesthesia (2%)
Ketan Karabhai Parmar, Aayush Multispecialty Hospital, India